RxDoctor Payments Data

Wael Richeh, MD

Neurology · Rancho Mirage, CANPI 1770894560

Payments from drug & device makers

$11,684in general payments, 2019–2025

Across 704 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$858
  • Novartis$724
  • UCB, Inc.$707
  • Supernus Pharmaceuticals, Inc.$618
  • Amgen$584
  • plus $7K from 44 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$11,47698%
  • Education$1912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,684 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$588,674
Medicare patients
1,526
Services billed
35,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate124$617,570
AubagioTeriflunomide31$286,500
Gamunex-CImmune Globul G/Gly/Iga Avg 4635$273,389
Kesimpta PenOfatumumab18$191,414
Radicava OrsEdaravone12$160,765
Aimovig AutoinjectorErenumab-Aooe162$135,049
Nurtec OdtRimegepant Sulfate85$126,835
IngrezzaValbenazine Tosylate12$114,348
MayzentSiponimod12$113,226
TecfideraDimethyl Fumarate11$97,006
VumerityDiroximel Fumarate11$93,340
BriviactBrivaracetam55$88,482
Teriflunomide40$74,243
GlatopaGlatiramer Acetate11$73,892
AustedoDeutetrabenazine15$72,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$352$617,570124 claims
SanofiAubagio$69$286,50031 claims
Grifols USA, LLCGamunex-C$103$273,38935 claims
BiogenTecfidera, Vumerity$488$190,34622 claims
PfizerNurtec Odt, Lyrica$858$150,207110 claims
UCB, Inc.Briviact, Neupro$707$144,524112 claims
AbbVieQulipta, Ubrelvy$1,217$119,642104 claims
Neurocrine Biosciences, Inc.Ingrezza$65$114,34812 claims
NovartisMayzent$724$113,22612 claims
Teva Pharmaceuticals USA, Inc.Austedo$475$72,55315 claims
SK Life Science, Inc.Xcopri$532$64,14144 claims
Amneal Pharmaceuticals LLCRytary$200$23,45322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →